Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRIMAQUINE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
Radical cure of Plasmodium vivax and Plasmodium ovale malaria (FDA-approved),Prophylaxis of Plasmodium vivax relapse following treatment of acute infection
Treatment of acute attacks of vivax malaria due to Plasmodium vivax,Radical cure of vivax malaria (elimination of hypnozoites),Suppression of malaria (prophylaxis) in areas with chloroquine-sensitive P. vivax
15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
Terminal elimination half-life of approximately 4-7 hours; in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, half-life may be prolonged due to accumulation in erythrocytes
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Primaquine is metabolized primarily by CYP1A2 and CYP3A4; also undergoes monoamine oxidase (MAO) metabolism. Metabolites include primaquine carboxy metabolite.
Chloroquine: hepatic metabolism via CYP2C8 and CYP3A4; primaquine: hepatic metabolism via CYP2D6 and other enzymes.
Primarily renal (60-65% as unchanged drug and metabolites); small amounts in feces (<5%)
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
Approximately 90-95% bound to plasma proteins, primarily to albumin
Chloroquine: 50-65% bound to albumin; Primaquine: ~20% bound to albumin.
Apparent volume of distribution (Vd) approximately 2.5-3.5 L/kg, indicating extensive tissue distribution, including high concentrations in erythrocytes and liver, which is relevant for anti-relapse activity
Chloroquine: Vd 100-200 L/kg (extensive tissue distribution); Primaquine: Vd 3-5 L/kg (moderate distribution). Clinical meaning: large Vd of chloroquine indicates deep tissue compartments with slow release.
Oral bioavailability is approximately 96%, with peak plasma concentrations reached within 1-3 hours
Both: Oral bioavailability ~80-90% for chloroquine; ~90% for primaquine. No parenteral form for this combination.
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment due to potential accumulation.
For chloroquine: GFR 10-50: 50% dose; GFR <10: 25% dose. For primaquine: No adjustment required, but monitor for hemolysis in GFR <10 due to accumulation.
Contraindicated in severe hepatic impairment; use with caution in mild-to-moderate impairment, reduce dose by 50% in Child-Pugh B, avoid in Child-Pugh C.
For chloroquine: Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or avoid. For primaquine: Child-Pugh A/B: no data, use with caution; Child-Pugh C: contraindicated due to risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency and impaired clearance.
0.3 mg/kg (base) orally once daily for 14 days; maximum 15 mg/day.
Chloroquine: 10 mg base/kg orally once daily for 2 days, then 5 mg base/kg once daily (max 300 mg base/day) for 2 weeks. Primaquine: 0.5 mg base/kg orally once daily for 14 days (max 30 mg base/day). Ensure G6PD screening before use.
No specific dose adjustment, but monitor for hemolytic effects due to age-related decline in G6PD activity.
Use lower end of adult dose for chloroquine due to reduced renal function; adjust according to Cr Cl. For primaquine, monitor for G6PD deficiency and hemolysis; dose as per adult. Consider increased risk of QT prolongation with chloroquine.
Primaquine can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Screen all patients for G6PD deficiency before prescribing.
Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Test for G6PD deficiency before starting therapy.
Hemolytic anemia in G6PD deficiency – screen and monitor,Methemoglobinemia – monitor for signs especially in infants and G6PD-deficient patients,QT interval prolongation – use with caution with other QT-prolonging drugs,Hematologic toxicity – monitor CBC in prolonged therapy
Hemolytic anemia (especially G6PD deficiency), bone marrow suppression, prolonged QT interval, visual disturbances (retinopathy with chloroquine), methemoglobinemia, and severe hypersensitivity reactions.
G6PD deficiency (absolute),Concurrent use of quinacrine (due to increased toxicity),Pregnancy (safe alternative not established; risk of hemolysis in G6PD-deficient fetus),Lactation if infant is G6PD deficient
G6PD deficiency (primaquine), known hypersensitivity to chloroquine or primaquine, porphyria, concurrent use of drugs with known hemolytic potential, pregnancy (based on risk-benefit), and severe liver or kidney disease.
Take with food to reduce gastrointestinal irritation. No specific food restrictions, but avoid alcohol as it may increase risk of adverse effects.
No clinically significant food interactions reported. However, antacids containing magnesium or aluminum can reduce chloroquine absorption; separate administration by at least 4 hours. Grapefruit juice may increase chloroquine levels via CYP3A4 inhibition; avoid concurrent use.
Primaquine crosses the placenta. In the first trimester, fetal G6PD deficiency increases risk of hemolytic anemia. Second and third trimesters: potential for fetal methemoglobinemia. Risk of hemolysis in G6PD-deficient fetuses; contraindicated in pregnancy except for severe malaria treatment when no alternatives exist.
In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuses. Second and third trimesters: chloroquine is safe, but primaquine should be avoided as fetal G6PD status is unknown.
Primaquine is excreted into breast milk in small amounts. M/P ratio not established. Risk of hemolysis in G6PD-deficient infants. Avoid breastfeeding in women with infant G6PD deficiency; use caution.
Chloroquine is excreted into breast milk in low concentrations; M/P ratio is approximately 0.5-0.6. Primaquine is excreted in breast milk; M/P ratio not well established. Breastfeeding is generally considered safe if infant is G6PD normal, but caution is advised due to potential for hemolysis in G6PD-deficient infants.
Pregnancy reduces primaquine exposure via increased clearance; however, due to teratogenicity and hemolytic risk, dosing adjustments are not recommended; alternative antimalarials preferred.
Chloroquine: No dose adjustment required; pharmacokinetics are not significantly altered. Primaquine: Contraindicated in pregnancy due to risk of hemolytic anemia in the fetus; no dose adjustment is applicable as it is not recommended.
Primaquine is the only agent active against hypnozoites of Plasmodium vivax and P. ovale, preventing relapse. Screen for G6PD deficiency before use; hemolysis risk. Administer with food to reduce GI upset.
Combination of chloroquine and primaquine is used for radical cure of P. vivax and P. ovale malaria. Chloroquine is effective against blood-stage parasites; primaquine eradicates hypnozoites in the liver. Screen for G6PD deficiency before initiating primaquine to prevent hemolytic anemia. Concurrent use with hematotoxic drugs (e.g., dapsone) increases hemolysis risk. Contraindicated in G6PD-deficient patients, pregnancy, and breastfeeding unless no alternative. Monitor for QT prolongation, especially with electrolyte abnormalities or concurrent QT-prolonging agents.
Take with food to decrease stomach upset.,Report any signs of hemolysis: dark urine, yellow skin/eyes, fatigue.,Complete full course even if symptoms improve.,Avoid concurrent use with other drugs that cause hemolysis.,Inform your doctor of any history of favism or G6PD deficiency.
Take with food or milk to reduce gastrointestinal upset.,Complete full course regardless of symptom resolution to prevent relapse.,Avoid alcohol during treatment due to risk of disulfiram-like reaction.,Report signs of hemolysis: dark urine, jaundice, pallor, fatigue (especially if G6PD deficient).,Do not take antacids containing magnesium or aluminum within 4 hours of chloroquine as they reduce absorption.,Seek medical attention for visual disturbances, QT prolongation symptoms (palpitations, syncope), or severe GI distress.,Use effective contraception during and for 1 month after treatment due to potential fetal harm from primaquine.
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRIMAQUINE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, answered by our medical review team.
PRIMAQUINE is a Antimalarial that works by Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a Antimalarial that works by Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRIMAQUINE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRIMAQUINE is: 15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.. The standard adult dose of ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is: Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRIMAQUINE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRIMAQUINE is classified as Category D/X. Primaquine crosses the placenta. In the first trimester, fetal G6PD deficiency increases risk of hemolytic anemia. Second and third trimesters: potential for fetal methemoglobinemi. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is classified as Category D/X. In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuse. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.